How Payers Are Driving the Site-of-Care Shift

Posted by Prateek Harsh on November 11, 2019

With all of the recent news from payers, 2019 is the year that the floodgates opened for ambulatory surgery centers (ASCs). This belief of mine was reinforced when I attended the 2019 Becker's ASC Annual Meeting, which took place Oct. 24-26 in Chicago. Payers, commercial or government, know that ASCs are about half of the cost of a hospital and have amassed increasing evidence of equal if not better outcomes than the hospital itself for the appropriate patient pool. These groups are now making big moves to realize significant cost savings from shifting the site of care.


>
Read More

Despite More Sophisticated Compensation Methods, Are Medtech Companies Set Up for Success?

Posted by Varun Chodha on October 28, 2019

Life sciences companies have come a long way since the days when they relied on sales reps building relationships with healthcare providers. As the industry moves from an individual, relationship-heavy selling model to a value-based model, today’s sales reps must engage non-clinical stakeholders within hospitals and IDNs in addition to doctors and medical staff. It’s no longer just about discussing the latest features and charging a premium. Now, companies are being challenged to provide better outcomes at lower costs. On top of all this, achieving growth is harder than ever in an increasingly saturated market.


>
Read More

To Rent or to Buy? In Data Analytics, That Is the Question.

Posted by Maria Kliatchko on October 23, 2019

Which capabilities should a company build for itself, and which should it outsource to a vendor? Since the outsourcing era began about 30 years ago, this question has been pondered by generations of leaders. Some companies use specialized partners for everything, going as far as to say that only people with the potential to become the CEO should be employed. They believe that every specialist should be hired from outside because requirements continuously change, and it’s always easier to find a partner than reskill, rehire and lay off their own people. Other companies err on the side of insourcing, believing that it helps them to do things less expensively and protect their IP.


>
Read More

Innovation Is Healthcare’s New Normal

Posted by Pratap Khedkar on October 17, 2019

This blog post was originally published on ZS's pharma blog, The Active Ingredient.

Sometimes it’s hard to keep in mind that healthcare was once considered a stodgy, conservative industry—at least by outsiders. Advances in care development and delivery happened, but the healthcare experience was generally the same as it had been decades before, as were the business models leveraged across the healthcare landscape. We’d grown, maybe not comfortable with, but accepting of the status quo.


>
Read More

Transcatheter Technology 2.0: How to Win in the New Marketplace

Posted by Sundeep Karnik on October 8, 2019

 

Transcatheter technologies transformed the treatment of coronary artery disease. From the first  percutaneous balloon angioplasty in 1977, to the first self-expanding stent in 1986 and first drug-eluting stent in 1999, to the biodegradable and bioresorbable stents we have today, many millions of patient lives have been saved and billions in economic value created.


>
Read More